Vernal is excited to announce its new partnership with REPROCELL, furthering our mission to democratize access to mRNA, a life-changing technology, around the world. REPROCELL is a trusted leader in iPSC reprograming technologies and GMP iPSC manufacturing based in Japan. Together with REPROCELL, we…
Find our latest article on Businesswire here: Vermont-based CDMO, Vernal Biosciences Announces an Additional $20MM in Funding to Expand GMP mRNA and LNP Manufacturing Click the orange “Contact Us” button in the top right hand corner to find out more!
Every success has an origin story. Check out this new VT Digger article on how CEO Christian Cobaugh, Ph.D. founded Vernal Biosciences, and what makes Vernal uniquely situated to meet mRNA process development and manufacturing needs.
After a successful extension of its Series A funding, Vernal Biosciences was featured in an Endpoints News article by Tyler Patchen. Find out how we are using these funds to widen our offerings and support the mRNA community, then click…
Vernal’s mRNA platform manufacturing capabilities have gotten the attention of the mRNA community. Read Pharma’s Almanac’s expose on Vernal here: Platform Processes and End-to-End Capabilities Position Vernal Biosciences as a Critical CDMO Resource for mRNA Developers (pharmasalmanac.com)
Seven Days wrote a great follow up article on Vernal’s growth since the summer of 2021. Click the link below to see what we’ve been up to. What a difference a year makes! New Companies Are Riding Vermont’s Health Tech…
Local NBC affiliate NBC5 came to visit Vernal Bioscience to discuss the eventual move to a new, larger facility in Essex and our plans to nearly quadruple our workforce. Watch the story on NBC5.
Vernal produces high-purity mRNA to supply to companies that develop mRNA-based health treatments. Read the full story at VTDigger.